Discontinued — last reported Q4 '24
Moderna Collaboration revenue — Additions increased by 400.0% to $5.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 58.3%, from $12.00M to $5.00M. Over 3 years (FY 2021 to FY 2024), Collaboration revenue — Additions shows a downward trend with a -23.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong business development success and the acquisition of new funding or milestone commitments from partners.
This represents new amounts billed or received from collaboration partners that are added to the deferred revenue balanc...
Comparable to 'New Contract Bookings' or 'Additions to Deferred Revenue' in companies with long-term service or R&D contracts.
mrna_segment_collaboration_revenue_additions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.00M | $5.00M | $4.00M | $3.00M | $3.00M | $2.00M | $8.00M | $2.00M | $11.00M | $6.00M | $12.00M | $3.00M | $3.00M | $1.00M | $5.00M |
| QoQ Change | — | -61.5% | -20.0% | -25.0% | +0.0% | -33.3% | +300.0% | -75.0% | +450.0% | -45.5% | +100.0% | -75.0% | +0.0% | -66.7% | +400.0% |
| YoY Change | — | — | — | — | -76.9% | -60.0% | +100.0% | -33.3% | +266.7% | +200.0% | +50.0% | +50.0% | -72.7% | -83.3% | -58.3% |